A. Quixadá

Genotoxicity associated with the use of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

R. Burbano, B. Cavalcanti, Marilena Facundo de Castro, 2018, Environmental and molecular mutagenesis.

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

R. P. Gonçalves, F. Duarte, M. C. Barbosa, 2012, Revista brasileira de hematologia e hemoterapia.

Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital

S. Magalhães, D. A. C. Cid, A. Quixadá, 2013, Revista brasileira de hematologia e hemoterapia.

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital

D. A. C. Cid, A. Quixadá, J. H. de Souza, 2013, Revista brasileira de hematologia e hemoterapia.

Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?

F. Duarte, M. C. Barbosa, R. Lemes, 2019, Hematology, transfusion and cell therapy.

Pancytopenia during tyrosine kinase inhibitor treatment – coexistence of chronic myeloid leukemia and visceral leishmaniasis: a case report

F. Duarte, R. Lemes, A. Quixadá, 2016, Journal of Medical Case Reports.